Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
30 participants
INTERVENTIONAL
2012-10-31
2014-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety, Efficacy and Tolerability of Vilazodone in Patients With Generalized Anxiety Disorder
NCT01766401
Safety, Efficacy and Tolerability of Vilazodone in (GAD) Generalized Anxiety Disorder
NCT01844115
Safety, Efficacy and Tolerability of Vilazodone in Generalized Anxiety Disorder
NCT01629966
Virtual Reality Exposure Therapy in the Intensive Treatment of Social Anxiety Disorder
NCT04977544
Acute Anxiolytic Effects of Riluzole on Subjects With Social Anxiety Disorder
NCT03017508
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Vilazodone
Vilazodone 20mg or 40mg taken once daily by mouth for up to 12 weeks
Vilazodone
Vilazodone 20mg or 40mg taken once daily by mouth
Placebo
Placebo to match Vilazodone 20mg or 40mg, taken once daily by mouth for up to 12 weeks
Placebo
Placebo matching Vilazodone 20mg or 40mg, taken once daily by mouth
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Vilazodone
Vilazodone 20mg or 40mg taken once daily by mouth
Placebo
Placebo matching Vilazodone 20mg or 40mg, taken once daily by mouth
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* LSAS total score of 70 at visits 1 and 2
Exclusion Criteria
* Current suicidal risk
* Current unstable medical condition
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Forest Laboratories
INDUSTRY
The Medical Research Network
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Michael R. Liebowitz, MD
Role: PRINCIPAL_INVESTIGATOR
The Medical Research Network, LLC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Medical Research Network, LLC
New York, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Careri JM, Draine AE, Hanover R, Liebowitz MR. A 12-Week Double-Blind, Placebo-Controlled, Flexible-Dose Trial of Vilazodone in Generalized Social Anxiety Disorder. Prim Care Companion CNS Disord. 2015 Nov 26;17(6):10.4088/PCC.15m01831. doi: 10.4088/PCC.15m01831. eCollection 2015.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
VII-IT-07
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.